Clinical Trial Update: Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) [Phase 3]

View source ↗

Summary

APROMISS is a Phase III trial of combined anlotinib and catequentinib in advanced alveolar soft-part sarcoma, leiomyosarcoma, and synovial sarcoma. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Leiomyosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• Anlotinib (anlotinib)
• Catequentinib (catequentinib)

Snippet

Sponsor: Advenchen Laboratories, LLC | Conditions: Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Status: RECRUITING